Prevention of postoperative recurrence of Crohn's disease by Adalimumab: A case series

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 4, 2012, Pages 468-470

  Savarino, Edoardo ^a   Dulbecco, Pietro ^a   Bodini, Giorgia ^a   Assandri, Lorenzo ^a   Savarino, Vincenzo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Adalimumab; Antitumor necrosis factor antibodies; Crohn's disease; Postsurgical relapse

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; MESALAZINE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; ILEOCECAL STRICTURE; INTESTINE OBSTRUCTION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CECUM; COMBINED MODALITY THERAPY; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ILEUM; MALE; MIDDLE AGED; RECURRENCE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84859360027     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283500849     Document Type: Article

References (20)

1. Sandborn WJ, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 2004; 127: 990-993. (Pubitemid 39208432)
2. Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy multi-centre trial. Gut 2010; 59:752e9.
3. Sorrentino D, Terrosu G, Avellini A, Maiero S. Infliximab and low dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn's disease. Arch Intern Med 2007; 167:1804-1810.
4. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136:441-450.
5. Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010; 8: 591-599.
6. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19:749-754. (Pubitemid 38496640)
7. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99:878-883. (Pubitemid 39090217)
8. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333.
9. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65. (Pubitemid 46108762)
10. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56:1232-1239. (Pubitemid 47300424)
11. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann Intern Med 2007; 146:829-838. (Pubitemid 351650483)
12. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127:723-729. (Pubitemid 39208405)
13. Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25:665-672. (Pubitemid 14122134)
14. D'Haens G, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114:262-267. (Pubitemid 28093532)
15. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956-963. (Pubitemid 20338451)
16. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualized ileal ulcers preceding symptoms. Gut 1992; 33:331-335.
17. Sachar DB. Recurrence rates in Crohn's disease: predicting the future and predicting the past. Gut 2006; 55:1069-1070. (Pubitemid 44085667)
18. Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104:2089-2096.
19. Rutgeerts P, Van assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128:856-861. (Pubitemid 40523538)
20. Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34:51-58.